Associated Papers
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2.
Wu CH et al.
Pathology, Research and Practice, 2024
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
Soon Jian Hao J et al.
Cold Spring Harbor Molecular Case Studies, 2022
PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study.
Kojima K et al.
Bmc Cancer, 2022
Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer.
Kahraman Çetin N et al.
Balkan Medical Journal, 2021
Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
Grosse C et al.
Plos One, 2019
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C et al.
Molecular Medicine Reports, 2018
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer.
Chen K et al.
The Journal of Thoracic and Cardiovascular Surgery, 2017
Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.
Belchis DA et al.
Oncotarget, 2016
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G et al.
Oncotarget, 2015
Determining lower limits of detection of digital PCR assays for cancer-related gene mutations.
Milbury CA et al.
Biomolecular Detection and Quantification, 2014
Molecular profiling of small cell lung cancer in a Japanese cohort.
Wakuda K et al.
Lung Cancer (amsterdam, Netherlands), 2014
EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
Stella GM et al.
Journal of Cancer Research and Clinical Oncology, 2013
Molecular pathology of lung cancer: key to personalized medicine.
Cheng L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2012
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.
van Eijk R et al.
Plos One, 2011
A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
Schuurbiers OC et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL et al.
Plos One, 2007
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005